Epilepsy and Seizure News
Neurofeedback News
Rewiring Your Brain: Neurofeedback Goes Mainstream -
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Will Strahl walked up to my door with a massive black briefcase in his ...
What Is Neurofeedback Therapy And How Does It Work? -
Ashwini Nadkarni, M.D., is a board-certified psychiatrist, Assistant Professor at Harvard Medical School and Interim Vice Chair for Faculty Affairs in the Department of Psychiatry at Brigham and Women ...
What Is Neurofeedback? -
Whenever I mention that neurofeedback helped me regain my life after my multiple brain injuries — or that I’m now a neurofeedback provider — the first reaction is to ask me, what is neurofeedback? I’m ...
Neurofeedback Gains Popularity and Lab Attention -
You sit in a chair, facing a computer screen, while a clinician sticks electrodes to your scalp with a viscous goop that takes days to wash out of your hair. Wires from the sensors connect to a ...
Brain training with neurofeedback shows enhanced benefits on cognitive functions -
Neurofeedback has been used for decades to reinforce healthy brain functions. With previous research reporting a positive correlation between enhanced brain activities during brain training and ...
Medical News Today
PubMed
Epilepsy as a Multiscale Network Disorder: Integrating Precision Therapeutics and Emerging Experimental Platforms -
Background/Objectives: Epilepsy remains a major neurological disorder, with approximately one-third of patients continuing to experience pharmacoresistant seizures despite the availability of numerous antiseizure medications (ASMs). While current therapies primarily target neuronal hyperexcitability through modulation of ion channels and neurotransmitter systems, increasing evidence suggests th...
Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound-Indication Matching and Precision Neurotherapeutic Development -
Background: Minor phytocannabinoids engage CB(1) and CB(2) receptors, as well as broader receptors and ion-channel targets. However, fragmented evidence limits translation into central nervous system (CNS) therapeutics. This review introduces pharmacological switching, defined as a dose-, state-, or model-dependent shift in the dominant determinant of a compound's net effect that reverses the d...
Targeted Sequencing and Haplotype Analysis of Voltage-Gated Potassium Channel Genes Reveal a Potential Association of KCNV2 Haplotypes with Antiseizure Medication Response in Turkish Patients with ... -
Objective: Voltage-gated potassium channel genes are among the most frequently implicated in epilepsy and antiseizure medication (ASM) response. In this pilot study, we aimed to identify rare and common variants by sequencing voltage-gated potassium channel (Kv) genes in epilepsy patients using ASM, and to reveal the potential drug responses of these variants. Methods: To investigate the role o...
RFX3 Pathogenic Variants as a Rare Cause of Infantile Epileptic Spasms Syndrome -
Regulatory Factor X3 (RFX3-OMIM#601337) encodes a transcription factor that is highly expressed in the human brain, particularly during neurodevelopment. It has been previously associated with neurodevelopmental disorders, including autism spectrum disorder (ASD), intellectual developmental disorder, and attention-deficit/hyperactivity disorder. However, the neurological and epileptic features ...
Glucose Transporter Type 1 Deficiency Syndrome: Clinical Variability and Challenges in Ketogenic Diet Management in a Paediatric Case Series -
Background/Objectives: Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a rare neurometabolic disorder caused by pathogenic variants in the SLC2A1 and a treatable cause of epilepsy and movement disorders. We aimed to describe clinical variability, diagnostic pathways and treatment outcomes in a paediatric case series, with a focus on ketogenic diet management. Methods: We retrospect...
IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy -
Background/Objectives: Isocitrate Dehydrogenase (IDH)1/2-mutant diffuse gliomas represent a biologically distinct subgroup of adult brain tumors in which eary metabolic reprogramming and accumulation of the oncometabolite D-2-hydroxyglutarate (D-2HG) drive epigenetic, immunologic, and clinical characteristics, including a high burden of glioma-associated epilepsy. This review summarizes the mol...
Science Daily